{
    "clinical_study": {
        "@rank": "112581", 
        "arm_group": [
            {
                "arm_group_label": "Erbium plus cosmetics plus Impact", 
                "arm_group_type": "Active Comparator", 
                "description": "Erbium 2940 plus cosmetics plus Impact Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact."
            }, 
            {
                "arm_group_label": "Erbium 2940 plus cosmetics", 
                "arm_group_type": "Active Comparator", 
                "description": "Erbium 2940 plus cosmetics Patient shall be treated with erbium 2940nm laser, cosmetics"
            }, 
            {
                "arm_group_label": "Erbium 2940 plus cosmetics plus Impact", 
                "arm_group_type": "Active Comparator", 
                "description": "Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact."
            }, 
            {
                "arm_group_label": "Erbium 2940nm plus cosmetics", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients shall be treated with Erbium 2940nm laser plus cosmetics only."
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the safety and efficacy of an  ablative fractional, 2940-nm laser combined with\n      the US Impact and cosmetic -formulations for improving the appearance of wrinkles, acne\n      scars and pigmented skin."
        }, 
        "brief_title": "Epidermal Delivery of Ani-Aging Ingredients", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Wrinkles", 
            "Acne Scars", 
            "Pigmentation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acne Vulgaris", 
                "Cicatrix"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, split face & dorsal hand side by side study. The purpose of the side\n      by side study is to determine whether the use of the Impact with the ablative fractional\n      2940nm laser  and cosmetics improves the cosmetic  outcomes when compared to using just the\n      ablative fractional 2940nm laser with the cosmetics.\n\n      This is a non-significant risk aesthetic clinical study. Only cosmetic formulations will be\n      used during the study,  These cosmetic formulations do not contain any ingredient\n      categorized as a drug by the FDA."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female in good general health between 35 to 65 years of age.\n\n          -  Must be willing to execute informed consent. Patient must also consent to having\n             photos taken at each visit.\n\n          -  A potential subject must exhibit:\n\n        Facial wrinkling, acne scars or pigmentation.\n\n          -  For FEMALE PATIENTS OF CHILDBEARING POTENTIAL, must have had a regular menstrual\n             cycle prior to study entry (a female is considered of childbearing potential unless\n             she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral\n             tubal ligation) and is willing to use an acceptable form of birth control during the\n             entire course of the study [i.e., acceptable methods of birth control are oral\n             contraceptives, contraceptive patches/rings/implants Norplanit\u00ae, Depo-Provena\u00ae,\n             double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies of\n             partner with a documented second acceptable method of birth control should the\n             subject become sexually active].  All systemic birth control measures must be in\n             consistent use at least 30 days prior to study participation.\n\n          -  Must be willing to comply with study visits and complete the entire course of the\n             study.\n\n        Exclusion Criteria:\n\n        Subjects meeting any of the following criteria will be excluded from participation:\n\n        The following are exclusion criteria for subjects in this study:\n\n          -  A subject that underwent a laser / light  treatment on the face within 12 months, or\n             any topical treatment on the face with 6 months.\n\n          -  A subject with any UNCONTROLLED systemic disease.  A potential subject in whom\n             therapy for a systemic disease is not yet stabilized will not be considered for entry\n             into the study.\n\n          -  A subject with a significant history or current evidence of a medical, psychological\n             or other disorder that, in the investigator's opinion, would preclude enrollment into\n             the study.\n\n          -  A subject using any topical product containing a retinoid, retinol, or other vitamin\n             A derivative within 3 months prior to or during the study period.\n\n          -  A subject using any systemic steroid therapy within 6 months prior to or during the\n             study period.\n\n          -  A subject that has been treated with Botox/Dysport or filler/biostimulatory molecule\n             injections to his/her face within the past six months.\n\n          -  A subject using any topical medicated creams, lotions, powders, etc. on the treatment\n             areas during the study period, other than the study treatment regimen within 14 days.\n\n          -  A subject that has previously been treated with systemic retinoids within the past\n             year (e.g., Accutane\u00ae, Roche Dermatologics).\n\n          -  A subject with recently excessive facial exposure to sunlight or artificial UV light\n             (e.g.: use of tanning beds/booths and/or sunbathing).  During the study, when\n             excessive sun exposure is unavoidable, subjects must wear appropriate protective\n             clothing (e.g. hat) and comply with the study dosing regimen of daily application of\n             the dispersed sunblock.\n\n          -  A subject with a recent history or active presence of any facial skin\n             condition/disease that might interfere with the diagnosis or evaluation of study\n             parameters (i.e.  moderate to severe acne vulgaris, atopic dermatitis, psoriasis,\n             rosacea, seborrheic dermatitis, excessive facial hair or coloration).\n\n          -  A female subject who is pregnant, nursing an infant or planning a pregnancy during\n             the study [throughout the course of the study, women of child-bearing potential must\n             use reliable forms of contraception (i.e., oral contraceptive, intrauterine device,\n             abstinence, or spermicides and condoms used in combination)].\n\n          -  Current participation or participation within 30 days prior to the start of this\n             study in a drug or other investigational research study.\n\n          -  Subjects who are pregnant, breast-feeding, or planning a pregnancy.  Females of\n             childbearing potential, must be either:\n\n          -  using the same form (i.e. brand) and dosage regimen of an oral contraceptive pill or\n             of a hormonal implant continuously for three months prior to study entry and continue\n             during the entire study, or\n\n          -  willing to use a different form of birth control during the study other than any form\n             of hormonal methods such as oral contraceptive pills and hormonal implants 30 day\n             prior to study entry and during the entire study period. For the purpose of this\n             study, the following are considered acceptable methods of birth control:\n             double-barrier methods (e.g.: condoms and spermicide), abstinence and vasectomies of\n             partner with a documented second acceptable method of birth control should the\n             subject become sexually active."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01847066", 
            "org_study_id": "ALMA 013-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Erbium plus cosmetics plus Impact", 
                    "Erbium 2940 plus cosmetics plus Impact"
                ], 
                "description": "Laser used in all arms", 
                "intervention_name": "Erbium 2940 plus cosmetics plus Impact", 
                "intervention_type": "Device", 
                "other_name": "Laser"
            }, 
            {
                "arm_group_label": [
                    "Erbium 2940 plus cosmetics", 
                    "Erbium 2940nm plus cosmetics"
                ], 
                "description": "laser", 
                "intervention_name": "Erbium 2940 plus cosmetics", 
                "intervention_type": "Device", 
                "other_name": "Laser"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "wrinkles", 
            "acne scars", 
            "pigmentation"
        ], 
        "lastchanged_date": "May 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York City", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10028"
                }, 
                "name": "NY Derm LLC"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Fractional Erbium 2940nm Laser & Impact US for Trans-Epidermal Delivery of Cosmetic Anti-Aging Ingredients for Wrinkles, Acne Scars and Pigmented Skin: A Randomized Split Face & Dorsal Hand Side by Side Study", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "An independent panel of qualified blinded physicians (masked) with respect to subject-identity, photo chronology, treatment methodology (with/without Impact module), study time point, and treatment assignment will grade the photographs as determined by:\nClinical Photographs Alexiades-Armenakas Grading Scale Assessment\nClinical Photographs Acne Scar Grading Scale (see section 7.1)\nClinical Photographs Hand Pigmentation Grading Scale (see section 7.1)\nSpectrophotometric (Reflectance Spectroscopy) Analysis of La*b* values", 
            "measure": "Clinical Photographs to determine improvement of appearance", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01847066"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Alma Lasers Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alma Lasers Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}